NEKTAR THERAPEUTICS
StreetZero Signal 49
About NEKTAR THERAPEUTICS
Nektar Therapeutics is a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy. Headquartered in San Francisco, California, the public company (Nasdaq: NKTR) was founded in 1990 and operates with a B2B business model. It is advancing candidates such as rezpegaldesleukin in Phase III trials for atopic dermatitis and alopecia areata, following prior partnerships including one with Bristol Myers Squibb.
LATEST FUNDINGRule 144
$15K
Announced 2026-11-17
TOTAL RAISED2.10B USD
IN THE NEWS
- ๐ Nektar Therapeutics Raises $250M in Public Offering
- ๐ Nektar Therapeutics
- ๐ Nektar Therapeutics Announces Pricing of $100 Million Public Offering
- ๐ Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX | Nektar Therapeutics
- ๐ Nektar Therapeutics Announces Public Offering of Shares of Common Stock | Nektar Therapeutics
EMPLOYEESโ
FOUNDED1990
HQSan Francisco, California, United States
Industry
Public Equity (NASDAQ)
Tags
BiotechnologyImmunotherapyPublic CompanyClinical-Stage
Key highlights
- Raised $250M via public offering in April 2026 to fund Phase III trials for rezpegaldesleukin.
- Completed $30M private placement with TCGX in March 2024.
- Public company on Nasdaq (NKTR) with prior partnership valued at $3.6B with Bristol Myers Squibb.
- Total funding across rounds reached $2.10B with investors including New Enterprise Associates and AstraZeneca.
Ask StreetZero about NEKTAR THERAPEUTICS
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account